These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29324253)

  • 1. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
    Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
    J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic.
    Ganetsky VS; Salzman M; Carroll G; Heil J; Sutton J; Visioli VM; Currie S; Schmidt R; Baston KE; Haroz R
    J Addict Med; 2023 Jan-Feb 01; 17(1):108-110. PubMed ID: 36166670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
    Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
    J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
    Andraka-Christou B; Page C; Schoebel V; Buche J; Haffajee RL
    Addict Sci Clin Pract; 2022 Aug; 17(1):43. PubMed ID: 35945636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
    Wenzel K; Selby V; Wildberger J; Lavorato L; Thomas J; Fishman M
    J Subst Abuse Treat; 2021 Jun; 125():108306. PubMed ID: 34016297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.
    Lai M; Bowman J; Charles J; Smid MC
    J Addict Med; 2023 May-Jun 01; 17(3):342-345. PubMed ID: 37267186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
    Kosten T; Aharonovich E; Nangia N; Zavod A; Akerman SC; Lopez-Bresnahan M; Sullivan MA
    Addict Behav; 2020 Dec; 111():106538. PubMed ID: 32777606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 17. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

  • 18. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
    Mannelli P; Douaihy AB; Akerman SC; Legedza A; Fratantonio J; Zavod A; Sullivan MA
    Am J Addict; 2022 Mar; 31(2):142-147. PubMed ID: 35137481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.